A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : GPs / Gypenosides

[Related PubMed/MEDLINE]
Total Number of Papers: 21
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   GPs  (>> Co-occurring Abbreviation)
Long Form:   Gypenosides
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2022 Gypenosides Prevent and Dissolve Cholesterol Gallstones by Modulating the Homeostasis of Cholesterol and Bile Acids. 12alpha-OH, ABC, BAs, CG, GO, KEGG, LD
2021 Gypenosides Inhibit Inflammatory Response and Apoptosis of Endothelial and Epithelial Cells in LPS-Induced ALI: A Study Based on Bioinformatic Analysis and in vivo/vitro Experiments. ALI, DEGs, GO, KEGG
2021 [Study on effect of gypenosides on insulin sensitivity of rats with diabetes mellitus via regulating NF-kappaB signaling pathway]. CRP, FBG, GLUT4, HOMA-IR, IL-1beta, IL-6, ISI, NF-kappaB, p-Akt, p-IkappaBalpha, p-IRS-1, p-p65, T2DM, TNF-alpha, Tyr
2019 Formulation design, characterization, and in vitro and in vivo evaluation of nanostructured lipid carriers containing a bile salt for oral delivery of gypenosides. NLCs
2018 Gypenosides as natural emulsifiers for oil-in-water nanoemulsions loaded with astaxanthin: Insights of formulation, stability and release properties. AST
2018 Gypenosides attenuate lipopolysaccharide-induced neuroinflammation and anxiety-like behaviors in rats. BDNF, IL-1beta, IL-6, LPS, NF-kappaB, TLR4
2018 Gypenosides Attenuate Lipopolysaccharide-Induced Neuroinflammation and Memory Impairment in Rats. BDNF, IL-1beta, IL-6, iNOS, LPS, NF-kappaB, TLR4
2018 Gypenosides attenuate lipopolysaccharide-induced optic neuritis in rats. GFAP, LPS, NF-kappaB, RGCs, STAT
2018 Gypenosides improve diabetic cardiomyopathy by inhibiting ROS-mediated NLRP3 inflammasome activation. CRPs, DCM, HG, ROS
10  2017 Gypenosides Ameliorate Carbon Tetrachloride-Induced Liver Fibrosis by Inhibiting the Differentiation of Hepatic Progenitor Cells into Myofibroblasts. AST, CK19, Col I, HPCs
11  2017 Gypenosides ameliorate memory deficits in MPTP-lesioned mouse model of Parkinson's disease treated with L-DOPA. CREB, L-DOPA, MPTP, NMDA, PD, TH
12  2017 Gypenosides Inhibits Xanthine Oxidoreductase and Ameliorates Urate Excretion in Hyperuricemic Rats Induced by High Cholesterol and High Fat Food (Lipid Emulsion). ADA, FEUA, GDA, LE, SCr, SUA, UA, UCr, uUA, XDH, XOD
13  2015 Gypenosides attenuate the development of L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned rat model of Parkinson's disease. L-DOPA, LID, PD
14  2015 Mechanism of action of gypenosides on type 2 diabetes and non-alcoholic fatty liver disease in rats. ALT, AST, BG, CYP450, PPARgamma, T2DM-NAFLD, TC, TG
15  2014 Gypenosides attenuate cholesterol-induced DNA damage by inhibiting the production of reactive oxygen species in human umbilical vein endothelial cells. ---
16  2014 Gypenosides protected the neural stem cells in the subventricular zone of neonatal rats that were prenatally exposed to ethanol. FASD, NSCs, SVZ
17  2013 Gypenosides pre-treatment protects the brain against cerebral ischemia and increases neural stem cells/progenitors in the subventricular zone. GFAP, MCAO, NSCs, SVZ
18  2013 The immunological adjuvant activity of gypenosides liposome against Newcastle disease vaccine. BL, GPSL, ND
19  2010 Gypenosides inhibit renal fibrosis by regulating expression of related genes in rats with unilateral ureteral obstruction. CTGF, TGF-ss1, UUO
20  2010 Gypenosides protects dopaminergic neurons in primary culture against MPP(+)-induced oxidative injury. PD, TH
21  2006 Gypenosides protect primary cultures of rat cortical cells against oxidative neurotoxicity. gamma-GCS, GR